纖維肌痛治療市場規模、佔有率和成長分析：按藥物類別、分銷管道和地區分類 - 產業預測，2024-2031 年

Fibromyalgia Treatment Market Size, Share, Growth Analysis, By Drug class, By Distribution Channels, By Region - Industry Forecast 2024-2031

出版日期: 2024年07月12日 | 出版商:

SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

纖維肌痛治療市場規模預計在 2022 年達到 13 億美元，從 2023 年的 13.9 億美元增至 2031 年的 23.9 億美元，預計複合年成長率為 7.00%。

纖維肌痛症是一種慢性疼痛疾病，其特徵是廣泛的疼痛、疲勞以及睡眠不安和情緒低落等其他症狀。它影響著世界上大約 2% 的成年人口，其中女性患病率高於男性。儘管進行了廣泛的研究，但目前尚無法治療方法纖維肌痛。然而，有多種治療方法可以緩解症狀並提高生活品質。治療方法通常包括藥物治療、生活方式調整和非藥物治療。其目的是緩解疼痛、改善睡眠模式、解決心理挑戰並提高您的整體幸福感。纖維肌痛治療很複雜，需要根據您的個人需求和反應制定治療計劃。

市場概況
北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲國家地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 其他亞太地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲 (MEA)
- 海灣合作理事會國家
- 南非
- 其他中東/非洲地區

競爭格局

前5名企業對比
主要企業市場定位（2023年）
主要市場參與者所採取的策略
近期市集活動
主要企業市場佔有率（2023年）

主要企業簡介

Pfizer Inc.（United States）
Eli Lilly and Company（United States）
Johnson & Johnson（United States）
Teva Pharmaceutical Industries Ltd.（Israel）
Daiichi Sankyo Company, Limited（Japan）
AbbVie Inc.（United States）
Pfizer（United States）
Boehringer Ingelheim International GmbH（Germany）
GlaxoSmithKline plc（United Kingdom）
AstraZeneca PLC（United Kingdom）
Mylan NV（Netherlands）
Sanofi SA（France）
Merck & Co., Inc.（United States）
Bayer AG（Germany）
Novartis AG（Switzerland）
Roche Holding AG（Switzerland）
Biogen Inc.（United States）
Allergan plc（Ireland）
Bristol Myers Squibb（United States）
Celgene Corporation（United States）

簡介目錄

Product Code: SQMIG35A2821

Fibromyalgia Treatment Market size was valued at USD 1.3 billion in 2022 and is poised to grow from USD 1.39 billion in 2023 to USD 2.39 billion by 2031, growing at a CAGR of 7.00% in the forecast period (2024-2031).

Fibromyalgia is a chronic pain disorder characterized by widespread pain, fatigue, and additional symptoms such as sleep disturbances and mood swings. It affects approximately 2% of the global adult population, with a higher prevalence among women than men. Despite extensive research, there is currently no cure for fibromyalgia. However, various treatments are available to help alleviate symptoms and enhance the quality of life for those affected. Treatment approaches typically include medications, lifestyle adjustments, and non-pharmacological therapies. The objective is to alleviate pain, improve sleep patterns, address psychological challenges, and enhance overall well-being. The complex nature of fibromyalgia management underscores the need for personalized treatment plans tailored to individual needs and responses.

Top-down and bottom-up approaches were used to estimate and validate the size of the Fibromyalgia Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Fibromyalgia Treatment Market Segmental Analysis

Global Fibromyalgia Treatment Market is segmented based on drug class, distribution channels, and region. Based on drug class, the market is segmented into antidepressants, antiepileptic, muscle relaxants, and others. Based on distribution channels, the market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Drivers of the Fibromyalgia Treatment Market

Several factors contribute to the expansion of the global fibromyalgia treatment market, primarily driven by the rising prevalence of fibromyalgia on a global scale. According to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), approximately five million adults aged 18 and older are affected by fibromyalgia in the United States alone. Notably, 80 to 90 percent of fibromyalgia patients are women, underscoring the significant impact of this condition on the female population. Increased awareness of fibromyalgia and advancements in diagnostic capabilities are also fostering greater recognition of the disorder worldwide.

Restraints in the Fibromyalgia Treatment Market

The scarcity of drugs approved specifically for treating fibromyalgia has resulted in only three available options. Consequently, there is growing reliance on off-label medications and personalized antidepressants to manage the disease's symptoms. In June 2019, Pfizer's loss of patent protection for Lyrica, the initial drug approved for fibromyalgia treatment, had a profound impact on its market revenue. The expiration of patent protection allowed generic versions of Lyrica to enter the market, intensifying competition and leading to a subsequent decline in overall market value.

Market Trends of the Fibromyalgia Treatment Market

Major players in the global fibromyalgia treatment market are actively pursuing innovative therapies to sustain or expand their market presence. The introduction and approval of emerging treatments for fibromyalgia are expected to significantly contribute to market growth during the forecast period. One notable example is galcanezumab, developed by Eli Lilly & Co., which is currently undergoing Phase IV clinical trials from January 2021 to December 2021 specifically for treating fibromyalgia. This expansion into new indications underscores the commitment of leading pharmaceutical companies to address the complex and evolving requirements of fibromyalgia patients.

Introduction

Objectives of the Study
Definitions
Market Scope

Research Methodology

Information Procurement
Secondary & Primary Data Sources
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Market Overview Outlook
Supply Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Dynamics
- Drivers
- Opportunities
- Restraints
- Challenges
Porters Analysis
- Competitive rivalry
- Threat of Substitute Products
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Technology Analysis
Pricing Analysis
Value Chain Analysis
Ecosystem of the Market
Start-up Analysis
Regulatory Landscape
Innovation Matrix
Top Investment Analysis
Key Success Factor
Market Attractive Index
Degree of Competition

Global Fibromyalgia Treatment Market by Distribution Channels

Market Overview
Hospital pharmacies
Retail pharmacies
Online pharmacies

Global Fibromyalgia Treatment Market by Drug class

Market Overview
Antidepressants, Antiepileptic
Muscle relaxants
Others

Global Fibromyalgia Treatment Market Size by Region

Market Overview
North America
- USA
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America
- Brazil
- Rest of Latin America
Middle East & Africa (MEA)
- GCC Countries
- South Africa
- Rest of MEA

Competitive Landscape

Top 5 Player Comparison
Market Positioning of Key Players, 2023
Strategies Adopted by Key Market Players
Recent Activities in the Market
Key Companies Market Share (%), 2023

Key Company Profiles

Pfizer Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Eli Lilly and Company (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Johnson & Johnson (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd. (Israel)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Daiichi Sankyo Company, Limited (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Pfizer (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim International GmbH (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AstraZeneca PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mylan N.V. (Netherlands)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi S.A. (France)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co., Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG (Germany)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche Holding AG (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biogen Inc. (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Allergan plc (Ireland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol Myers Squibb (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celgene Corporation (United States)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments